The lead proprietary name reviewer for GW Pharmaceuticals PLC's Epidiolex (cannabidiol) deemed the proposed trade name unacceptable over a series of safety concerns, but she was ultimately overruled by her managers who disagreed with the totality of her conclusions.
Briana Rider, a safety evaluator in US FDA's Division of Medication Error Prevention and Analysis (DMEPA), specifically worried about potential confusion between the name Epidiolex and